Article citationsMore>>
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P.B., Cormio, G., Sorio, R., Cavazzini, M.G., Ferrandina, G., Breda, E., Murgia, V., Sacco, C., Cinieri, S., Salutari, V., Ricci, C., Pisano, C., Greggi, S., Lauria, R., Lorusso, D., Marchetti, C., Selvaggi, L., Signoriello, S., Piccirillo, M.C., Di Maio, M., Perron, F., Multicentre Italian Trials in Ovarian Cancer (MITO-7), Groupe d'Investigateurs Nationaux pour l’Etude des Cancers Ovariens et du sein (GINECO), Mario Negri Gynecologic Oncology (MaNGO), European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10), Gynecologic Cancer InterGroup (GCIG) Investigators. (2014) Carboplatin plus Paclitaxel Once a Week versus Every 3 Weeks in Patients with Advanced Ovarian Cancer (MITO-7): A Randomised, Multicentre, Open-Label, Phase 3 Trial. The Lancet Oncology, 15, 396-405.
https://doi.org/10.1016/S1470-2045(14)70049-X
has been cited by the following article:
-
TITLE:
Three Weeks Carboplatin/Paclitaxel versus Weekly Regimen in Egyptian Women Cohort Treated for Ovarian Carcinoma
AUTHORS:
A. Mounir, E. E. Ibrahim
KEYWORDS:
Epithelial Ovarian Carcinoma, Carboplatin/Paclitaxel, Weekly versus Every Three Weeks
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.12 No.2,
February
19,
2021
ABSTRACT: Introduction: Epithelial Ovarian Carcinoma (EOC) comprises the vast
majority (almost 90%) of ovarian carcinomas. Chemotherapy is the main treatment
in ovarian cancers. The standard of care in the chemotherapeutic is the combination
of a platinum (carboplatin or cisplatin) and a taxane (paclitaxel or docetaxel).
Studies were done to determine whether this combination to be given weekly or every
3 weeks. Patient and Method: Inclusion criteria: 1) Female patients between
the ages of 17 - 78 years. 2) Baseline hematological, renal and liver laboratory
profiles were within accepted ranges. 3) Performance status of the patients was
0-II. 4) Patients were pathologically proven ovarian cancer. 5) A follow-up period
for at least 6 months was required. Exclusion criteria: 1) Patients who had double
malignancy were excluded. 2) Performance status more than II. 3) Other comorbidity. Results: We reviewed 69 female patients with EOC, with 60% received every
three weeks regimen. Mean age was 53.22 years. At a median follow up of 45.9 months,
there was no significant different between the two protocols in terms of mean PFS,
62.35 months (95% CI: 50.08 - 74.63 months) for the three-weekly cohort, and 69.25
months (95% CI: 55.24 - 83.26 months) for weekly protocol (p = 0.613). The three
weekly regimen patients had a higher incidence of hospital admission (40% vs 18.5%
for the weekly protocol patients), but it didn’t reach a statistical significance
(p = 0.063). The three weekly protocol had a significantly higher incidence of causing
a neutropenic fever (p = 0.003). Conclusion: In our cohort of Egyptian women
with EOC, no significant difference in PFS was found when compared the weekly Carboplatin/paclitaxel
when compared to the classic three weeks, although the weekly protocol may be causing
less febrile neutropenia and fewer hospital admissions.
Related Articles:
-
Maja L. Rudolph, Michael Rabinoff, Bruce L. Kagan
-
Philippe Chassy
-
M. Charfeddine, Malek Gassoumi, H. Mosbahi, C. Gaquiére, M. A. Zaidi, H. Maaref
-
Bernardin Ahouty, Mathurin Koffi, David Courtin, Ilboudo Hamidou, Didier Sokouri, Innocent Abé, Laure Gineau, Thomas Konan, Lingué Kouakou, Tidou Abiba Sanogo, Enock Matovu, Bruno Bucheton, Vincent Jamonneau, Simon-Pierre N’Guetta
-
Chun Yang, Zhaoda Zhang